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BACKGROUND: The ACTION trial was initiated to provide evidence from a randomised trial on the effects of chemotherapy in women
aged over 70 years where evidence for risk and benefit are lacking.
METHODS: This was a randomised, phase III clinical trial for high risk, oestrogen receptor (ER) negative/ER weakly positive early breast
cancer. The trial planned to recruit 1000 women aged 70 years and older, randomised to receive 4 cycles of anthracycline
chemotherapy or observation. The primary endpoint was relapse-free interval. The trial included a pilot phase to assess the
acceptability and feasibility of recruitment.
RESULTS: The trial opened at 43 UK centres. Information on number of patients approached was available from 38 centres. Of the 43
eligible patients that were approached, 39 were not randomised due to patients declining entry. After 10 months only 4 patients had
been randomised and after discussion with the research funder, the trial was closed and funding terminated.
CONCLUSION: Despite widespread support at several public meetings, input from patient groups including representation on the Trial
Management Group, the trial failed to recruit due to the inability to convince patients to accept randomisation. It would therefore
seem that randomising the patients to receive chemotherapy vs observation is not a viable design in the current era for this patient
population.
British Journal of Cancer (2011) 105, 1260–1266. doi:10.1038/bjc.2011.377 www.bjcancer.com
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Breast cancer is the most common malignancy in women in the
western world, affecting one in nine women at some time in her life,
with over 41000 new cases and 13000 deaths each year in the United
Kingdom alone. In 2006, 33% (12532) of new cases in the United
Kingdom were in women aged 70 or over (He´ry et al, 2008).
The increased incidence is primarily as a result of an ageing
population and the changing lifestyle factors of that population, for
example, later age at first birth, with the median age of onset being
B65 years. Projected population forecasts in Western countries
indicate that the proportion of older women will increase
dramatically over the next 50 years (Yancik, 1997; Vercelli et al,
1998), which will result in a significant increase in the number of
older women diagnosed with breast cancer. However, data from
the EUROCARE II study (Vercelli et al, 1998) show that patients
aged 65 to 99 diagnosed with breast cancer had a relative risk of
cancer-related death at 1 year of 1.7 compared with those aged
55–64, although this reduced to 1.09 at 5 years. The reduction in
mortality is therefore not uniform across all age ranges, with
the 50% of women who present with the disease over the age of
70 years appearing to benefit least from recent advances
(Bouchardy et al, 2007).
Endocrine therapy, with either tamoxifen or aromatase inhibi-
tors, is routinely used for older patients with hormone responsive
disease. Clinical trials are currently examining age-related varia-
tions in surgical care and radiotherapy (Turner et al, 1999; Wyld
et al, 2004). However, the best management for older patients with
high-risk disease, which is not hormone responsive, remains
uncertain. The general observation of improvements in survival
with respect to breast cancer are essentially confined to women
agedo70 (Autier et al, 2011). It may not be coincidental that this
age-associated cancer-specific survival is mirrored by the use of
cytotoxic chemotherapy for early stage disease in younger patients.
With an average life expectancy of 15.3 years for a 70-year-old
woman in the United Kingdom (Government Actuary’s Depart-
ment, 2006), the potential to gain a significant number of life years
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amply justifies research aimed at better targeting of chemotherapy
treatment. Despite this, clinical trials evaluating adjuvant chemo-
therapy in this age group are sparse. A study of patients enrolled
in 164 Southwest Oncology Group trials in the United States
(Hutchins et al, 1999) found that patients aged 65 and over were
underrepresented in trials, with only 9% of patients enrolled in
breast cancer trials aged over 65, despite 49% of breast cancer
patients being in that age group. The findings were similar when
trials excluding older patients were omitted from the analysis.
ADJUVANT CHEMOTHERAPY FOR EARLY STAGE
BREAST CANCER
The EBCTCG overview of 60 trials of prolonged polychemotherapy
vs no chemotherapy involving 36 000 women has confirmed that,
adjuvant anthracycline-based chemotherapy reduces the annual
odds of death by 38% (s.e.¼ 5), for women under 50 years of age at
diagnosis and by 20% (s.e.¼ 4) in women aged 50–69 years of age
(EBCTCG, 2005). A reduction in recurrence emerges chiefly during
the first 5 years of follow-up, whereas the survival advantage grows
throughout the first 10 years. Subgroup analyses of these data have
provided further information about relative benefit of treatment by
age and oestrogen receptor (ER) status.
Estimates for those aged over 70 years appear consistent with
those for women aged 60–69 years, however, as only 1200 women
are included in the published meta-analysis, firm conclusions
cannot be drawn. Moreover, the observed association with age may
be confounded by other differences, notably the increasing
proportion of patients with ER-positive tumours.
However more recent research has identified a sub-population
of elderly women with ER-positive disease who are at high risk of
relapse (Durbecq et al, 2008), particularly those whose tumours
show amplifications of HER2.
The lack of reliable trial data has led to a great disparity in the
use of cytotoxic chemotherapy in early breast cancer patients aged
over 70. There are no agreed protocols for selecting patients
whether ER negative or ER positive with other risk factors, yet
control of breast cancer is the most likely determinant of survival
where co-morbid disease is limited (Clarke, 2006). Studies have
shown that treatment is often less intensive in older patients
irrespective of co-morbidity (Yancik et al, 1989; Bergmann et al,
1991; Martin et al, 1996; Lavelle et al, 2007), suggesting that
perceived frailty rather than specific co-morbidities may have a
role in determining the use of chemotherapy for which a lack of
efficacy data could further influence the treatment decision.
The ACTION study was conceived out of an international
interest in optimising treatment for older patients, and was to be
one study within a comprehensive international portfolio run via
the Breast International Group, EORTC, the International Breast
Cancer Study Group and the International Collaborative Cancer
Group, addressing the main question of whether older patients
should be offered chemotherapy.
PATIENTS AND METHODS
The ACTION Trial was a randomised controlled trial testing
whether adjuvant chemotherapy (either doxorubicin 60mgm2 or
epirubicin (90mgm2 plus cyclophosphamide 600mgm2 given
thrice weekly for four cycles) improves the outcome in older
women with high risk, ER negative/ER weakly positive breast
cancer. An optional second randomisation comparing standard
3-weekly therapy with accelerated 2-weekly therapy with GCSF
support aimed to test the acceptability and tolerability of this
regimen within this patient group (Figure 1).
Required staging investigations were in keeping with standard
evidence-based practise in breast cancer management (including
FBC, biochemical screen, CXR) and all patients had to have normal
cardiac function (ECHO or MUGA) with further staging investiga-
tions only if clinically indicated. Inclusion criteria (Table 1)
included age 470 years (either gender) and WHO performance
status 0 or 1 with a diagnosis of invasive primary breast cancer,
which had been surgically treated by wide local excision or
mastectomy with clear margins (41m apart from deep margin
if full thickness resection). Axillary staging was performed by
sentinel node biopsy, axillary sampling or clearance with all
patients found to be node positive having had axillary clearance or
radiotherapy to the axilla. In addition, patients had to have been
assessed as being at high risk of relapse within 5 years, indicated
by usual prognostic factors of tumour size, grade, lymph node
status and ER score. Other constraints were that patients had to be
fit to receive chemotherapy, if allocated, including adequate bone
marrow, hepatic and renal function and no active infection.
Patients were required to give written informed consent;
randomisation was to take place as soon as reasonably possible
after definitive surgery (ideally within 8 weeks) and the patient was
to be available for routine long-term hospital follow-up.
Previous exposure to anthracycline chemotherapy or mantle
radiotherapy at any time required exclusion as did inoperable
breast cancer (T4 and/or N3 disease), a contraindication to or
patient choice not to have radiotherapy following breast-conser-
ving surgery. Patients were not eligible if they had had a previous
invasive breast cancer, DCIS treated systemically or any other
systemic therapy within the last 5 years. Patients with any previous
haematological malignancy or melanoma at any time were also
ineligible.
Inclusion of the first 200 patients was designated the pilot phase
and aimed to test the viability of recruiting patients in the 70þ
year age group to a trial of chemotherapy vs no chemotherapy and
to evaluate the tolerability and acceptability of treatment. An
accrual rate of B25 patients per month, a patient acceptance rate
of 25% and 200 patients recruited within 1 year would have
indicated viability of continuing to the full study. The pilot phase
also included a comprehensive quality of life study.
Throughout the pilot phase, centres were asked to voluntarily
complete detailed screening logs of all patients aged over 70 who
had received primary surgery for invasive breast cancer (Figure 2).
Anonymised data on reasons for ineligibility and reasons for
patients declining study entry were collected regularly, allowing a
review of eligibility criteria. Results of the pilot phase were to be
reviewed by an Independent data Monitoring Committee to inform
the design and viability of the main trial.
Randomisation
No
chemotherapy
Chemotherapy
(AC or EC x4)
Randomisation 2
(optional)
3 weekly
administration
2 weekly
administration
+pegylated GCSF
Figure 1 Trial design.
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Following successful completion of the pilot phase, the primary
endpoint was to be the relapse-free survival interval (RFI),
including as events any local or distant relapse, contralateral and
ipsilateral breast second primary cancers, breast cancer deaths at
any time and all deaths within 4 months or randomisation.
The rationale for the choice of endpoint was to evaluate the most
sensitive assessment of breast cancer outcome whilst ensuring that
any early excess in mortality during treatment was duly
incorporated. Secondary endpoints included disease-free survival
(for completeness and comparison with other studies), overall
Table 1 Principal inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
K Aged over 70
K Male or female
K WHO performance status 0 or 1
K Histological diagnosis of early stage invasive breast carcinoma
K Primary operable breast cancer surgically treated by wide local excision
or mastectomy with clear margins
K Axillary staging performed (node-positive patients to have axillary clearance
or radiotherapy to the axilla)
K Fit to receive chemotherapy
K Adequate bone marrow, hepatic and renal function
K No active, uncontrolled infection
K Written informed consent
K Available for routine long-term hospital follow-up
K Previous invasive breast cancer within the last 5 years
K Previous DCIS within the last 5 years if treated systemically
K Previous haematological malignancy or melanoma
K Chemotherapy within the last 5 years
K Previous anthracycline chemotherapy at any time
K Primary inoperable breast cancer (T4 and/or N3 disease)
K Breast-conserving surgery with no plans for postoperative radiotherapy
K Previous mantle radiotherapy
K Significant cardiac disease
K Unable or willing to give informed consent
Changes made in July 2008
High risk of relapse within 5 years
ER negative or ER weakly positive (Allred score p5)
Any previous systemic anti-cancer therapy, or any solid tumour in the
last 5 years
was changed to was changed to
High risk (B30%), includes patients with HER2-positive disease and/or
ER-negative disease, or ER positive with grade 3 disease and/or 4+ positive nodes
No previous anthracycline chemotherapy at any time, and no systemic
anti-cancer therapy within the last 5 years
Abbreviations: DCIS, ductal carcinoma in situ; ER¼ oestrogen receptor; WHO¼World Health Organization. Randomisation was as soon as reasonably possible after definitive
surgery, ideally within 8 weeks.
Centre / Hospital
State month
1. How many potential patients have been screened to go into the ACTION trial this month?
   (Patients 70 with a breast cancer diagnosis)
2. Out of the total number of potential patients how many were:
3. Of those eligible how many were approached to go into the study?
4. Of those approached how many were randomised into the study?
5. Of those approached how many refused to go into the study?
6. Please indicate the reasons for patient refusal:
Did not want chemotherapy
Worried about side effects
Worried about ability to cope alone
Worried about other health conditions
Coult not decide
Wanted chemotherapy
Other (please state)
8. Additional comments on patient eligibility
9. Any other issues causing delay and non approach of trial to patients?
Total number of patients screened at your centre
to date (inc patients screened this month)
Other (please state)
Significant cardiac disease
Previous invasive cancer within last 5 years
Not fit enough to receive trial chemotherapy
Unable to give informed consent
Low risk ER positive
Inoperable breast cancer
Did not have surgery
7. Please indicate the reasons for ineligibility:
Ineligible for the study?
Number of patients
YearMonthDay
Date
Eligible for the study?
Completed by
Trial Audit Form
Number of patients
Previous systemic therapy in last 5 years OR
previous anthracycline therapy (please specify below)
Previous mantle or breast radiotherapy/
(please specify below)
Figure 2 Screening log.
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survival, compliance, safety and tolerability of chemotherapy and
patient-assessed quality of life.
In addition, a biological study was proposed to investigate
markers of resistance to chemotherapy, to provide a basis for
exclusion of patients from ineffective treatment in the future. This
trial population was likely to provide one of the few remaining
opportunities to study the natural history and biology of breast
cancer in an elderly population as trials in breast cancer
comprising a no-treatment arm, irrespective of the age of the
patient, are becoming less acceptable to patients. In the best
interests of patients, more trials are focusing on gathering
biological evidence for exclusion of patients from treatment with
agents that may result in toxicity but not efficacy.
The statistical assumptions underlying the ACTION trial design
were that the relapse rate in the control arm within 5 years would
be 30% in this ER negative/weakly positive disease group. A total
of 1000 patients were to be recruited over a 3-year period in the
main trial in order to have 80% power to detect an increase in RFI
from 70% to 77.9% (a 0.05, two sided).
RESULTS
Early feasibility exercises
Responses to a questionnaire circulated to UK breast oncologists
on 29 April 2003 indicated a high level of interest in a trial testing
the efficacy of adjuvant chemotherapy for older patients.
Completed questionnaires were received from 89 clinicians at 56
UK centres, the majority supporting a trial design comparing
anthracycline polychemotherapy with no chemotherapy. This
widespread and enthusiastic support encouraged the development
of the protocol and supported the successful application for
research funding (CTAAC, Cancer Research UK – CRUK/06/002).
Feasibility of ACTION The ACTION trial opened in July 2007,
with 43 centres opening to recruitment over the subsequent 18
months.
In the first year of recruitment 92 screening logs were returned
from 23 centres. A total of 272 patients had been screened of whom
21 (7.7%) were eligible for the trial. In all, 19 out of 21 eligible
patients were approached for trial entry and two had been
randomised (Table 2). Due to the voluntary nature of the screening
logs it is likely that the figure underestimates the number of
patients directly approached to enter the ACTION trial. Of those
patients approached who declined trial entry, most lacked
uncertainty over whether or not to undergo chemotherapy,
1 patient chose to receive chemotherapy and 10 elected not to
receive chemotherapy (Table 3). The most common reason for
ineligibility related to ER score (Table 4).
Although the inclusion criteria relating to ER status (i.e., ER
negative or weakly positive) had been devised to restrict the trial to
those at high risk of early relapse, screening logs and anecdotal
feedback suggested the restriction rendered ineligible a number of
patients who would be deemed at high risk of relapse irrespective
of their ER status (i.e., extensive nodal involvement, grade 3 etc).
In June 2008, therefore, a protocol amendment was implemented
to widen the eligibility criteria to more pragmatically include
patients assessed by their clinician to be at high risk of early breast
cancer relapse irrespective of hormone receptor status. Addition-
ally screening data led to agreement to allow inclusion of those
with previous solid tumours more than 5 years ago and HER2-
positive patients, with an allowance for herceptin to be given as per
local practise if deemed appropriate.
In the time between the protocol amendment and centres
receiving local approval of the change in eligibility, 27 screening
logs were returned from 17 centres with 79 patients screened. An
additional two patients were randomised to the study during this
period. After the eligibility changes were implemented a further
Table 3 Reasons for eligible patients declining to take part in ACTION
Screening data received
before June 2008
Screening data received
between June 2008 and local
R&D approval
Screening data received
after local R&D approval Total
n % n % n % n %
Number of eligible patients who refused trial 17 100 4 100 18 100 39 100
Did not want chemotherapy 10 58.8 4 100 13 72.2 27 69.2
Wanted chemotherapy 1 5.9 0 0 4 22.2 5 12.8
Worried about side effects 2 11.8 0 0 1 5.6 3 7.7
Wanted to make own decision
(no randomisation)
1 5.9 0 0 0 0 1 2.6
Unknown 3 17.6 0 0 0 0 3 7.7
Abbreviation: R&D¼ research and development committee.
Table 2 Summary of the screening data received before, during and after the change in eligibility
Screening data received
before June 2008
Screening data received
between June 2008 and local
R&D approval
Screening data received
after local R&D approval Total
n % n % n % n %
Total patients screened 272 100 79 100 151 100 502 100
Total eligible 21 7.7 6 7.6 21 13.9 48 9.6
Total approached 19 7 6 7.6 18 11.9 43 8.6
Total randomised 2 0.7 2 2.5 0 0 4 0.8
Total refused 17 6.3 4 5.1 18 11.9 39 7.8
Total ineligible 248 91.2 73 92.4 125 82.8 446 88.8
Total unknown eligibility 3 1.1 0 0 5 3.3 8 1.6
Abbreviation: R&D¼ research and development committee.
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54 screening logs were received from 27 centres with a total of 151
patients screened. A higher proportion of patients were eligible for
the trial as expected following the amendment (21 out of 151
(13.9%)) with 18 patients approached and no randomisations.
Again, the majority declined because they elected not to have
chemotherapy (13 patients). Patients who had ER-positive breast
cancer but who were deemed at low risk of early relapse were the
majority of those ineligible (Tables 1–3).
In November 2008, a decision was made by the Trial Manage-
ment Group, endorsed by the independent Trial Steering
Committee and the trial’s Sponsors, to close to further recruitment
after the organisation providing research funding chose not to
award the next annual installment of the grant on the grounds of
lack of viability. Follow-up was also terminated in the four
randomised patients.
DISCUSSION
An audit carried out at Southend General Hospital between 1 April
2004 and 30 September 2004 aimed to quantify the likely size of the
eligible trial population, and to evaluate the acceptability and
tolerability of four 3-weekly cycles of doxorubicin 60mgm2 and
cyclophosphamide 600mgm2 in breast cancer patients over 70
years of age. A total of 54 patients with early breast cancer (median
age¼ 78.0 years (IQR¼ 74–83)) were identified. In all, 52% lived
alone and 61% had co-morbid conditions (Johnson et al, 2005).
In all, 17 (31%) did not receive primary breast surgery, the
majority of whom (82%) were ER positive. Those who did not
undergo surgery were significantly older than those who did
undergo surgery (mean age 83.2 years (s.d. 6.6); Pp0.001), and
there was a suggestion of an association between not having
surgery and living alone (no surgeryþ living alone¼ 12 (71%) vs
surgeryþ living alone¼ 16 (43%); P¼ 0.06). Using the Nottingham
Prognostic Index (NPI) score, 17 (46%) of the 37 patients
undergoing surgery scored 4.4 or more, giving them a high risk
of relapse within 5 years. They would, therefore have been eligible
for ACTION. During the period of the audit, chemotherapy was
offered postoperatively to patients with at least one high risk
factor. A total of 13 patients were offered chemotherapy; 11 of
whom had an NPI44.4. Of those with NPI44.4 who were not
offered chemotherapy, two were considered too frail, and the
reason for the MDT decision for the remaining four was not
specified. In all, 6 of the 13 patients (46%) offered chemotherapy
accepted it. Those accepting chemotherapy had a mean age of 73.1
(s.d. 2.3) years. One (17%) lived alone and two (33%) had
co-morbidity. Treatment was well tolerated (no grade 3/4 toxicity),
and no patients required dose reductions or delays. Prophylactic
GCSF was not given and no patient required hospitalisation.
Although the numbers were small, the Southend audit suggested
Table 4 Reasons for ineligibility for the ACTION trial
Screening data
received
before June 2008
Screening data received
between June 2008
and local
R&D approval
Screening data
received after local R&D
approval Total
n % n % n % n %
Number of ineligible patients 248 100 73 100 125 100 446 100
Low risk ER+/Allred or quick score 45 126 50.8 33 45.2 43 34.4 202 45.3
Previous invasive cancer/metastatic
disease
39
(metastatic¼ 6)
15.7 9
(metastatic¼ 1)
12.3 14
(metastatic¼ 2)
11.2 62
(metastatic¼ 9)
13.9
Not fit enough to receive trial
chemotherapy
23 9.3 12 16.4 20 16 55 12.3
HER2 positive 18 7.3 0 0 0 0 18 4
Did not have surgery 4 1.6 2 2.7 9 7.2 15 3.4
Inoperable breast cancer 4 1.6 3 4.1 0 0 7 1.6
Significant cardiac disease 4 1.6 2 2.7 1 0.8 7 1.6
Previous systemic therapy 0 0 0 0 5 4 5 1.1
Unable to give informed consent 2 0.8 1 1.4 0 0 3 0.7
More than 8 weeks since surgery 2 0.8 0 0 0 0 2 0.4
Other 26 10.5 11 15.1 33 26.4 70 15.7
Investigator decision – not to give
chemotherapy
6 2.4 6 8.2 7 5.6 19 4.3
DCIS 6 2.4 0 0 4 3.2 10 2.2
Benign disease 4 1.6 0 0 2 1.6 6 1.3
Further surgery required 2 0.8 1 1.4 2 1.6 5 1.1
Investigator decision – to give
chemotherapy
4 1.6 0 0 0 0 4 0.9
Patient did not want active treatment 0 0 1 1.4 1 0.8 2 0.4
Neoadjuvant chemotherapy given 0 0 0 0 2 1.6 2 0.4
No axillary surgery 1 0.4 0 0 0 0 1 0.2
Investigator decision – not otherwise
specified
0 0 0 0 1 0.8 1 0.2
Paget’s disease of nipple only 0 0 1 1.4 0 0 1 0.2
Bilateral breast cancer 0 0 0 0 1 0.8 1 0.2
Pathology implies lymphoma 0 0 0 0 1 0.8 1 0.2
Node-negative disease 0 0 0 0 1 0.8 1 0.2
Patient did not attend clinic 0 0 1 1.4 0 0 1 0.2
Patient did not want to go in any
clinical trial
0 0 1 1.4 0 0 1 0.2
Patient in another trial 0 0 0 0 1 0.8 1 0.2
Awaiting test results 1 0.4 0 0 0 0 1 0.2
Unknown 2 0.8 0 0 10 8 12 2.7
Abbreviations: ER¼ oestrogen receptor; R&D¼ research and development committee.
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that an anthracycline-based chemotherapy regimen could be
delivered safely to selected patients aged 70þ with a high risk
of breast cancer relapse. Age and failure to undergo surgery are the
factors most likely to limit recruitment.
Given the level of enthusiasm identified before the launch of
ACTION, its failure to recruit sufficient patients to establish its
viability was particularly disappointing. There are number of
reasons, which contributed to this outcome. First, and in contrast
to the pre trial audit, a large number of patients who were screened
proved to be ineligible. The great majority of these were due to the
patients not being at high risk of recurrence within 5 years of
diagnosis due to a high ER score or low grade of tumour. Other
significant reasons included previous invasive cancer within the
past 5 years or patients deemed not fit for chemotherapy. Only a
small number of patients did not undergo surgery although there
may have been other patients who were not offered surgery in their
referring centres as the screening process was not comprehensive.
More than 400 patients were screened and 80% were ineligible for
the reasons given above. This proportion was much greater than
predicted by the preoperative audit and effectively demonstrated
that a clinical trial aiming to recruit more than 1000 patients over a
3-year period was not feasible. A patient information sheet was
provided to patients following their diagnosis and surgery. This
acknowledged that there was a perception of chemotherapy being
associated with increased toxicity in older patients. However, it
also stated that with modern chemotherapy this perception may
not be correct. We also said that we were selecting women over the
age of 70 who were in generally good health for this trial. This we
felt would reassure patients.
Unfortunately, the majority of the patients who were eligible and
were approached declined trial entry. In most cases this was due to
the patient not wishing to undergo chemotherapy although a
smaller proportion made an active choice for chemotherapy. This
study was not designed to investigate the patient’s reasons for
declining or accepting chemotherapy, but this is the subject of a
current study (AChEW: Ballinger et al, personal communication).
A subsequent non-randomised study, which seeks to correlate the
results of standard geriatric assessment tests with the toxicity of
subsequent chemotherapy is also planned (ACTION2) This will
enlarge upon the information gathered on patient’s attitudes to
chemotherapy in the elderly breast cancer patient.
Randomised trials that involve a comparison of significant toxic
complications with none have, not surprisingly, always presented
difficulties in recruitment. When provided with more complete
information about the benefits and risks of the different treatment
options before agreeing to randomisation the patients made their
own active, informed decisions. This is a well-recognised problem
in non-blinded randomised trials where the control group does not
receive active treatment. This is not likely to be due to a specific
feature of breast services in the United Kingdom as the no
treatment control arm of the European CASA trial also failed,
recruiting only eight patients. In the CASA trial the options
comparing standard chemotherapy with low-dose metronomic
chemotherapy faired slightly better recruiting B60 patients but
overall recruitment was inadequate and the trial also closed. More
recently a North American study comparing standard chemother-
apy (EC or CMF) with single agent capecitabine but without a no
treatment control group, successfully recruited more than 600
patients and demonstrated significant disease-free survival benefit
in the standard chemotherapy arm (Muss et al, 2009). Furthermore
the two mortalities in the study were in the experimental group
and overall toxicity in the standard chemotherapy arm was
acceptable. Drawbacks of this study included the recruitment of a
significant proportion of patients between the age of 65 and 70,
and the fact that capecitabine proved to be a rather toxic control
arm. However it does demonstrate that older patients are willing
and able to undergo chemotherapy within the context of a
randomised trial. Further evidence for the problems associated
with non-blinded randomised controlled trials comes from the
early closure of the ESTEeM trial evaluating the role of surgery in
frail elderly patients with primary operable breast cancer. In this
study, which compared primary endocrine therapy with surgery
and adjuvant endocrine therapy in patients over the age of 75,
there was no shortage of eligible patients. However despite initially
indicating a willingness to join the trial the great majority of
patients opted for one or other treatment (B60% surgery and 40%
primary endocrine therapy) and subsequently declined randomi-
sation. This adds further evidence to the increasing desire for older
patients to receive comprehensive information and to plan an
active role in decisions relating to treatment.
The chemotherapy trials listed above lack a no-treatment
control arm, so that the survival effect of the intervention is not
measurable on the natural history of the disease. They also do not
address the issue of patient fitness for treatment, which will be the
purpose of the next ACTION trial (ACTION2).
Conclusion
The pilot phase of the ACTION trial almost certainly represents the
last attempt in breast cancer to compare chemotherapy against no
chemotherapy within the context of a randomised controlled trial.
A similarly designed trial run via the IBCSG (CASA study), also
folded due to low recruitment, suggesting that the experiences of
the United Kingdom are not unique. There is a need to explore
other approaches to evaluate the risks and benefits of chemo-
therapy in selected older patients. Alternative strategies, including
investigating the use of both qualitative geriatric assessment tests
and quantitative biological tests in a non-randomised trial for the
elderly breast cancer patients are under development. The question
of selecting older patients for adjuvant chemotherapy will become
even more important in our ageing Western populations.
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